Scorpion venom, containing highly toxic, small polypeptides that diffuse rapidly within the patient, causes serious medical problems. Nanobodies, single-domain antigen-binding fragments derived from dromedary heavy-chain antibodies, have a size that closely matches that of scorpion toxins. Therefore these nanobodies might be developed into potent immunotherapeutics to treat scorpion envenoming. Multiple nanobodies of subnanomolar affinity to AahII, the most toxic polypeptide within the Androctonus australis hector venom, were isolated from a dromedary immunized with AahII. These nanobodies neutralize the lethal effect of AahII to various extents without clear correlation with the kinetic rate constants k on or k off , or the equilibrium dissociation constant, K D . One particular nanobody, referred to as NbAahII10, which targets a unique epitope on AahII, neutralizes 7 LD 50 of this toxin in mice, corresponding to a neutralizing capacity of approx. 37 000 LD 50 of AahII/mg of nanobody. Such high neutralizing potency has never been reached before by any other monoclonal antibody fragment.
INTRODUCTION
Humans are heavily exposed to hazardous scorpion stings in tropical and subtropical regions. For example 200 000 epidemiological cases are reported annually in Mexico [1] and approx. 30 000 in Tunisia, of which 1000 lead to systemic manifestations requiring admission into hospital [2, 3] . For the latter country, the scorpion Aah (Androctonus australis hector) is responsible for most of the recorded fatal stings [3] .
Polypeptides of approx. 65 amino acid residues are responsible for the noxious effects of scorpion venoms. These small proteins affect excitable cells by specific interaction with voltage-gated sensitive sodium channels [4, 5] . The most abundant toxic compound of the Aah venom, referred to as AahII [6] , has been purified [7, 8] and its structural and antigenic properties are well established [9] [10] [11] [12] [13] . AahII is also the most poisonous toxin of this North African scorpion with an LD 50 < 3 ng [i.c.v. (intracerebroventricular) administered in mouse of 20 g] [6] .
The current immunotherapy for scorpion envenoming uses purified polyclonal F(ab ) 2 fractions prepared from equine hyperimmune sera [3, 14] . Their manufacturing is tedious and F(ab ) 2 fragments may still exert adverse effects (e.g. anaphylactic shock) upon injection in the patient [15] [16] [17] . Thus the antivenom treatment of the scorpion sting remains controversial. In Brazil [18] and Mexico [1] its effectiveness in reducing the paediatric mortality is beyond any doubt, whereas in India [19] , Israel [20] and Tunisia [3, 17] the beneficial effects of scorpion antivenom to patients are uncertain. The reason for this low efficacy is ascribed, at least in part, to the large difference in MW (molecular mass) (and diffusion) between the F(ab ) 2 and the scorpion toxin [15] . It is therefore fair to conclude that there is room for improvement on the currently used anti-scorpion venom therapy.
The introduction of smaller, recombinant antigen-binding fragments derived from monoclonal antibodies is considered to be such an improvement on the current therapy. Indeed, one AahIIneutralizing murine monoclonal antibody (4C1) has been isolated [21] and was subsequently employed to develop a scFv (singlechain variable fragment) against AahII [22] . Another scFv, against the AahI toxin was identified [23] and further engineering led to the design of a bispecific scFv construct against the AahI and AahII toxins that protected mice against the Aah venom [24] . However, this bispecific antibody construct (MW of approx. 60 000 Da) would be of limited use to face the rapid kinetic diffusion of the toxin (MW approx. 7000 Da). Moreover, the NC (neutralizing capacity) remains moderate and its use as a human therapeutic might still generate an undesirable HAMA (human anti-mouse antibody) response. To avoid a possible HAMA response against the antivenom, human scFv antibody fragments were generated against the Cn2 toxin, the major toxic component of the new world scorpion Centruroides noxius [25] .
In the present study we propose a new antibody format, the recombinant VHH [variable domain of the heavy chain of a HCAb (heavy-chain antibody)] derived from a camel homodimeric HCAb lacking light chains [26] as a potential immunotherapeutic to combat scorpion envenoming. The VHH domain, also named Nb (nanobody), represents the smallest, intact, natural antigenbinding fragment. The small size (MW of approx. 15 000 Da), good stability, high level of expression in microbial systems, high solubility, good specificity, high affinity of Nbs for their cognate antigen and their close sequence identity with family III human VH makes them potentially valuable for therapeutic applications [26] [27] [28] [29] . In fact, the dromedary VHH sequence differs in two respects from a human VH [26, 30] . Secondly, the CDR3 loop of VHH is on average longer, and is often tethered to the CDR1 via an interloop disulfide bond. Previously, we immunized dromedaries with a heterogeneous scorpion toxic fraction (i.e. AahG50), and raised neutralizing HCAbs [31] . In the present study, we report the successful generation of a large 'immune' VHH library from the lymphocytes of a dromedary that was immunized with purified AahII, and retrieved after phage display multiple Nbs that recognize AahII with high affinity. From all of the recombinant antibodies, some of our AahII-specific Nbs show a 'best in class' scorpion toxin-neutralizing activity in mice. 
Venom and toxins
The Androctonus australis hector scorpions were electrically stimulated to release venom. The collected venom was fractionated over Sephadex G50 [31] and the toxic fraction was named 'AahG50'. Applying this AahG50 fraction on a Mono-S FPLC column (5/5 Mono-S; Pharmacia) followed by a 35 min (0.5 ml/min) gradient from 0 to 60 % ammonium acetate (of 0.05 M and 0.5 M), yielded an enriched AahII fraction (eluting at 45 % of the gradient) that was recognized by AahII-specific rabbit antibodies (gift from Dr C. Devaux, Faculté de Médecine Nord, Institut Jean Roche, Marseille, France). This fraction was further purified on a reverse-phase C 8 HPLC column (Beckman) in water with 0.1 % trifluoroacetic acid, using a 30 min (1 ml/min) gradient from 20 to 50 % of solution B (0.1 % trifluoroacetic acid in acetonitrile).
Escherichia coli strains and vectors
The phage-display vector pHEN4 [32] was employed to construct the VHH library, hosted in E. coli strain TG1. The Nbs selected by panning were recloned in the pHEN6 expression vector [33] . This vector encodes a PelB leader signal to secrete the Nb in the periplasm of E. coli strain WK6, and a C-terminal His 6 tag for affinity purification and detection of the recombinant Nb.
Dromedary immunization
The dromedary was injected s.c. (subcutaneous), five times (at days 0, 7, 14, 21 and 35) with an increasing amount of the AahII Mono-S-enriched fraction and then with the purified AahII toxin (80-100 μg at days 49, 57 and 64). To maintain the high titre of immunoglobulins (and antigen-specific B cells), the dromedary received three additional boosts of AahII (100 μg at days 94, 101 and 108). The first injection was in complete Freund's adjuvant and booster injections were in incomplete Freund's adjuvant.
Construction of an 'immune' VHH library
At 4 days after the last boost, over 100 ml of anti-coagulated blood was collected from which plasma and peripheral blood lymphocytes were isolated by centrifugation on Lymphoprep (Nycomed). Total RNA from approx. 10 8 lymphocytes was released in 4 ml of a solution containing 23.6 g of guanidine-SCN, 0.37 g of citric acid, 0.25 g of lauroyl sarcosine for 50 ml of RNase-free water (pH 7.0) by pushing the cell suspension through 19G and 23G needles. Then 400 μl of 2 M sodium acetate (pH 4.0), 4 ml of water-saturated phenol and 2 ml of chloroform/isoamylalcohol (24:1) were added to extract the RNA in the aqueous phase. After ethanol precipitation and dissolving the RNA in 300 μl of RNase-free water, 50 μg was used to prepare cDNA with 2.5 μg of dN 6 primers and Superscript-II reverse transcriptase (Invitrogen) following the manufacturer's protocol. The gene fragments encoding the variable domain up to the CH2 domain were amplified by PCR with the primers CALL001 (5 -GTCCTGCTGCTCTTCTACAAGG-3 ) and CALL002 (5 -GGTACGTGCTGTTGAACTGTTCC-3 ) annealing at conserved regions within the leader sequence and within the CH2 exon of the heavy-chain gene of all dromedary IgGs respectively. The 600 bp fragment (VHH-hinge-CH2 that lacks the CH1 exon) was eluted from an agarose gel after separation from the 900 bp fragment (VH-CH1-hinge-CH2 exons). This step eliminates the PCR product containing the classical VH genes. A nested PCR with primers annealing at the framework-1 (A6E: 5 -GATGTGCAG-CTGCAGGAGTCTGGRGGAGG-3 ; or SM17: 5 -CCAGCCG-GCCATGGCTGATGTGCAGCTGGTGGAGTCTGG-3 ) and framework-4 (38: 5 -GGACTAGTGCGGCCGCTGGAGA-CGGTGACCTGGGT-3 ) regions was performed on the purified HCAb containing a fragment to restrict the amplicon to the VHH-encoding region only and to introduce the restriction sites for PstI, NcoI or NotI (underlined in the primer sequences above).
The final PCR fragments were ligated, after restriction enzyme digestion, into the phagemid vector pHEN4 [32] cut with the same enzymes. For both libraries (PstI/NotI and NcoI/NotI), vectorligated material was transformed into E. coli electrocompetent cells (TG1) and plated on LB (Luria-Bertani)-agar plates supplemented with 100 μg of ampicillin/ml and 0.1 % glucose. The colonies were scraped from the plates, washed and stored at − 80
• C in LB medium supplemented with glycerol (50 % final concentration).
Selection of AahII-specific Nbs
The cloned VHH repertoire was expressed on phage after infecting a representative aliquot of the library with M13K07 helper phages. Recombinant phages were prepared by PEG [poly(ethylene glycol)]/NaCl precipitation. Phage particles carrying antigenspecific Nbs were enriched by three consecutive rounds of in vitro selection on AahII (10 μg/well) coated on microtitre plates (Nunc, Maxisorp). Residual protein binding sites on the plates were blocked at room temperature (22 • C) for 2 h with 1 % (w/v) casein in PBS. In the subsequent step, 10 11 phage particles were incubated per well for 1 h. After several washing steps with PBS, bound phage particles were eluted for 10 min with 100 μl of freshly prepared triethylamine [70 μl of triethylamine (99 %, Sigma) in 5 ml of water, pH 10.0]. The solution of the eluted virions was transferred to a tube containing 100 μl of 1.0 M Tris/HCl (pH 7.4) and was used to infect exponentially growing E. coli TG1 cells. An aliquot was properly diluted and plated on LB-agar with ampicillin. After the second and third round of panning, individual colonies were picked and infected with helper phages. The next day, the phage particles released into the culture medium were screened by phage ELISA on microtitre plates coated with 100 μl of AahII (1 μg/ml) [33] . The antigen specificity of the VHH for each clone scoring positive in phage ELISA was confirmed in a direct ELISA with the periplasmic extract from fresh cultures of the original clone induced with 1 mM IPTG (isopropyl β-D-thiogalactoside).
VHH sequence analysis
The VHH nucleotide sequence of each clone that scored positive in both ELISAs (phage ELISA and direct ELISA) was determined on an automated DNA sequencer (ABI prism 3100; Applied Biosystem). The nucleotide sequence was translated into its amino acid sequence.
Expression and purification of Nbs
The VHH genes were subcloned into the pHEN6 expression vector using restriction enzymes NcoI or PstI and BstEII [33] . The plasmid constructs were transformed into the non-suppressor strain of E. coli WK6 cells. Production of recombinant Nbs was performed in shaker flasks. Freshly transformed cells were grown at 37
• C in Terrific Broth supplemented with 0.1 % glucose and 100 μg of ampicillin/ml until an attenuance of 0.6-0.9 (at 600 nm), before induction with 1 mM IPTG and fermentation for 16 h at 28
• C. After pelleting the cells, the periplasmic proteins were extracted by osmotic shock [33, 34] . The recombinant protein was purified by two chromatographic steps: an IMAC (immobilized metal-affinity chromatography) on a His-select (Sigma) column followed by gel filtration on a Superdex-75 column (16/60; Pharmacia). The Nb-containing fraction was concentrated on a Vivaspin concentrator (VivaScience, Sartorius) with a MW cut-off of 5 kDa. The purity of the protein was checked on SDS/PAGE (12 % gel) under reducing and nonreducing conditions and stained with Coomassie Blue. The final yield of the purified Nb was determined from absorption at 280 nm using the theoretical molar absorption coefficient and MW, as calculated from the amino acid content of the Nb clone.
Determination of affinity constant and epitope complementation groups
Binding kinetics between Nb and toxin were assessed by SPR (surface plasmon resonance) (BIAcore-3000). The AahII antigen (5 μg/ml in 10 mM acetate buffer, pH 4.6) was immobilized on a CM5 sensor chip using N-hydroxysuccinimide-N-ethyl-N -(dimethylaminopropyl)-carbodiimide chemistry until 200 resonance units were immobilized. All measurements were performed at a flow rate of 30 μl/min in HBS buffer [10 mM Hepes (pH 7.5), 150 mM NaCl, 3.5 mM EDTA and 0.005 % Tween 20]. Various concentrations of the purified Nb were applied on to the chip to determine the association and dissociation rate constants, k on and k off (using the BIA-evaluation software version 4.1; BIAcore), from which we calculated the equilibrium binding constant, K D . After each measurement, the residual Nbs were cleared from the toxin on the surface with 10 mM glycine/HCl (pH 1.5).
To determine the epitope complementation group(s) of the Nbs, we injected an excess of a first Nb. After saturating the toxin on the sensor chip with this Nb and reaching equilibrium, we applied a second Nb in presence of the first Nb.
Toxicity and neutralization assays of AahII
Mice experiments were carried out in accordance with the European Community Council Directive (86/609/EEC) for experimental animal care, and all procedures were approved by the Institutional Research Board of the Pasteur Institute of Tunis. Groups of four mice were used to determine the LD 50 of the AahII toxin. A volume of 5 or 200 μl of 0.1% BSA and 0.15 M NaCl, containing increasing amounts of AahG50 or AahII toxin were individually injected by i.c.v. or s.c. routes respectively. Control animals received only physiological water (0.9 % NaCl). The LD 50 values were measured as described by BouhaoualaZahar et al. [34] . The survivors within each cohort of four mice that received the same amount of toxin were counted 24 h after injection. The average number of survivors was assessed from two independent experiments, and the LD 50 was expressed as the nanograms of AahII injected into a mouse whereby two out of the four mice survived.
To measure the toxin NC of the Nb, we employed the standard method to monitor the serotherapeutic batches of equine F(ab ) 2 , whereby antibodies (Nbs in our case) were premixed at a variable molar excess with an increasing amount of AahII or AahG50. As a control, animals received a mixture of 2 LD 50 of AahII with a 4 molar excess of purified Nb against AahI (NbAahI 22, [35] ) that does not crossreact with AahII. After a pre-incubation (90 min at 37
• C), a constant volume of 5 μl or 200 μl of the mixture was i.c.v. or s.c. injected respectively, in each mouse (cohorts of four mice). The number of mice surviving the treatment after a delay of 24 h was monitored. The NC was calculated according to the guidelines proposed by the World Health Organization (1981):
[NC (LD 50 /mg of Nb) = (LD 50 in the presence of Nb−LD 50 in the absence of Nb)/mg of Nb
RESULTS

AahII antigen preparation
The AahG50 fraction of scorpion venom obtained after Sephadex G50 chromatography was additionally fractionated on Mono-S and C 8 columns. The purified protein with a MW of 7249.40 Da (MS data) was characterized as AahII. The median lethal dose (LD 50 ) of this purified AahII in Swiss male mice (20 g in weight) was 3 ng or 250 ng after i.c.v. or s.c. injections respectively.
Humoral immune response elicited in the dromedary
To generate a large panel of high-affinity AahII-specific Nbs, we started from a hyperimmunized dromedary. Instead of immunizing with an AahG50 venom mixture (as performed previously [31] ), we immunized with an enriched fraction of AahII (Mono-S), followed by several boosts with C 8 -HPLC purified toxin. An antigen-specific response of high titre (> 1:5000) was raised after 5 weeks. This titre increased after boosts with the pure AahII to a final titre of at least 1:15 000. The AahII-specific immune response was present in both the conventional antibody and in the HCAb fractions.
Identification of AahII-specific Nbs
The blood lymphocytes of the immunized dromedary served to generate two 'immune' VHH libraries of 2 × 10 8 and 1.6 ×10 individual colonies (for NcoI/NotI and PstI/NotI libraries respectively). A PCR on 20, randomly chosen, clones from each library indicated that more than 85 % of the clones contained a phagemid with a VHH insert. After the second and third round of panning, 37 out of 48 randomly picked, individual colonies produce virions (after infection with helper phages) that recognize AahII in a phage-ELISA. The AahII specificity of the Nbs for a selection of 29 clones out of the 37 that scored positive in phage-ELISA was re-tested in a direct ELISA using the soluble proteins from the bacterial periplasm. In total, 28 out of the 29 periplasmic extracts were confirmed to contain AahII-specific Nbs. All of these extracts yielded a strong signal, except for clones NbAahII01, 23, 30 and 33 that gave a signal of only ∼ 2× the background signal (background signal is that obtained without immobilizing AahII in the wells). These clones and the one that scored negative (NbAahII47) in this periplasmic extract ELISA were not further analysed, except for their nucleotide and amino acid sequence.
Sequence analysis of selected Nbs
The Nb insert of all 37 clones were sequenced and the deduced amino acid sequences were aligned ( Figure 1 ) and numbered according to IMGT (ImMunoGeneTics) numbering [36] . Some clones differed by a few nucleotides but encoded the same amino acid sequence (silent mutations), these are only shown once in Figure 1 . The sequences are grouped into nine distinct clusters (named A-I) according to their CDR3 sequence similarity. For some clusters, the sequences contain only a few amino acid differences in their framework regions. In contrast, for other clusters, the sequences contain several amino acid differences, some of them even have a CDR1 or CDR2 that differs in length with other sequences from the same cluster. For example, in cluster F, clone NbAahII45 and NbAahII18 (or NbAahII08) have a CDR1 of 9 and 8 amino acids respectively.
The high sequence similarity in the CDR3 among the binders within a cluster most likely reflects an independent B-cell lineage that was at the origin of these Nbs. The clones that give a low signal in the direct ELISA are from cluster B. The single clone that fails to give a signal in the periplasmic extract ELISA is from cluster A.
Seven of these lineages (A-G) possess the characteristic VHH hallmark amino acids in their framework-2 region with an arginine or cysteine residue at position 50 [26, 30] . As expected for dromedary VHHs, binders from four out of the seven clusters have an extra pair of cysteine residues, besides the conserved Cys 23 and Cys 104 . For clones of clusters A, D and G, one extra cysteine residue is located in the CDR3 and one in the CDR1, whereas clones of cluster C have a cysteine residue in the CDR3 and one at position 50 (i.e. within framework-2). Remarkably, the sequences of one cluster (cluster E) contain only one single extra cysteine residue (in the CDR1). Two clusters (cluster H consisting of one isolated sequence, and cluster I of 14 sequences) contain the VH hallmark amino acids in the framework-2 region (e.g. a leucine residue at position 50). However, the presence of an arginine residue at position 118 instead of the conserved tryptophan residue shows that the domains of cluster I will fail to associate with a VL domain [30] . Therefore these clones are derived from HCAbs and do not reflect the VH domain that pairs with a VL in a classical antibody. The presence of the single clone NbAahII38 of cluster H is puzzling. It possesses the conserved Trp 118 in combination with the VH hallmark amino acids in framework-2. Therefore this binder might correspond to a VH domain derived from a conventional antibody, although, during the cloning of the library, all efforts were undertaken to avoid this fraction.
Table 1 Production yield of recombinant Nbs and their antigen interaction parameters
The production yield of purified Nb per litre of culture is given (last column). The association and dissociation rate constants (k on and k off ) to immobilized AahII were measured by SPR and used to calculate the equilibrium dissociation constant (K D ). The name of the actual Nb and the cluster to which it belongs are also given. 
Affinity measurement of AahII binders
To investigate the correlation between antigen-specificity (epitope), affinity and AahII toxin NC, we selected 12 clones distributed over all clusters (except clusters A and B, as the Nbs in the periplasmic extracts of these clones gave a poor signal to AahII in ELISA). The average yield of each purified Nb varied between 0.6 and 10.0 mg/l of bacterial culture (in shake flasks) ( Table 1 ). The affinity of the Nbs for AahII toxin was measured using SPR. An example of the affinity sensorgram is shown for NbAahII10 (Figure 2A (Table 1 ). The corresponding equilibrium constants (K D ) calculated for the individual binders ranged from 120 pM to 76 nM, and among these 12 clones, nine Nbs displayed low K D values in the subnanomolar range ( Table 1 ). The two clones from cluster F (NbAahII08 and NbAahII18) with three amino acid substitutions in their framework region, but otherwise sharing an identical sequence in their CDRs, possessed identical kinetic binding data for AahII. In contrast, the clones NbAahII05 and NbAahII39 from cluster G that differ by two amino acids in their CDR2 and four out of 11 amino acids in their CDR3, varied 4-fold in their K D values. Likewise, the four clones originating from cluster I (with slightly different CDR3 sequences) had K D values differing by a factor of 10.
Epitope complementation groups of AahII binders
To group the Nbs from the different sequence clusters according to their targeted epitope, we coupled the AahII toxin covalently on the biosensor chip and after saturating the toxin with one Nb, we monitored the possible binding of a second Nb ( Figure 2B ). No signal increase will be observed if the second Nb binds to an epitope overlapping that of the first Nb. In contrast, if the signal increase upon addition of the second Nb equals the signal obtained with this Nb alone (in the absence of the first Nb) then, evidently, these Nbs bind to non-overlapping epitopes. This approach was applied for multiple pairs of Nbs in both directions, i.e. clone NbX followed by binding of clone NbY and vice versa. The interpretation of the sensorgrams might get complicated when the association of the first Nb induces a conformational shift on a distantly located area of the antigen that hinders the subsequent binding of the second Nb. The results of the epitope complementation grouping are schematically represented in Figure 3 . First, it seems that all clones grouped within the same cluster (based on the CDR3 sequence length and homology) bind to the same epitope complementation group. Consequently, the CDR3 sequence that was used to define the clusters determines which epitope is targeted. Secondly, the antigen-binding sites of clones from clusters D and H (NbAahII17 and NbAahII38 respectively) relative to those of the other clones are identical. Their epitopes are therefore expected to have an extensive overlap. Thirdly, the antigenic site of the Nbs from cluster D, G and H overlaps with that of clones from clusters F and I, although the two latter binders have clearly an independent epitope. Fourthly, NbAahII36 representing cluster C binds to an independent site relative to the shared epitope of the Nbs from clusters D and H, although all of these Nbs fail to recognize the antigen that is in complex with either NbAahII05 or NbAahII18. Finally, clone NbAahII10, which was tested against binders of all other clusters, attaches to a unique epitope since all other Nbs could bind equally Figure 2B ). The epitopes of the Nbs of the various clusters are represented by circles; the NbAahII clone number and the cluster to which this clone belongs are given. Fixed-sized circles are used since the actual size of the footprint of the Nb on the toxin is unknown; the degree of overlap of the circles is also arbitrarily chosen, however, if circles do not overlap then the Nbs are not competing with each other for toxin binding. It seems that clones NbAahII20 and -12 of cluster I bind to an identical epitope, whereas clones NbAahII17 and -38 of clusters D and H respectively, bind to the same epitope complementation group. The epitope of NbAahII10 does not overlap with epitopes from other Nbs; however, the exact location of this epitope relative to the others therefore remains tentative. The black, grey and white colours of the circles refer to strong, intermediate and weak neutralization of AahII toxin respectively.
well to the toxin, independent of the prior presence or absence of NbAahII10 ( Figure 2B ).
NC of anti-AahII Nbs
The NC of the AahII-specific binders from each cluster was first evaluated by an i.c.v. injection of mice with a mixture of a particular Nb and the AahII toxin. This standard experimental approach has been shown previously to be effective to test various anti-toxin antibodies in a reliable manner consuming a minimal amount of material [22] [23] [24] 31, 34, 35] . It is a particularly useful test for toxins that are cumbersome to purify.
Neutralization of AahII toxin by Nbs tested by i.c.v. injection
Depending on the actual Nb, the neutralizing activity varied widely (Table 2 ). For example, the Nbs from clusters C, D and H at a 2-fold molar excess neutralized weakly (or not at all) the toxicity of the AahII. In contrast, each one of the five binders from sequence clusters F, G and I neutralizes in at least 50 % of the mice ∼ 3-4 LD 50 of AahII when tested at a 2-4 molar excess of Nb. This corresponds with a NC for these Nbs at a 4-molar excess to toxin of 27 000 LD 50 /mg of Nb (=400 LD 50 /nmol of Nb). Remarkably, under similar conditions, the NbAahII10 of cluster E neutralizes even higher toxic doses of the AahII toxin. Indeed, for a toxin/Nb ratio of 1:4, approx. 168 ng of NbAahII10 neutralizes 100 % of the toxicity of 7 LD 50 (21 ng) AahII and 240 ng of this Nb neutralized in 50 % of the mice the toxicity of 10 LD 50 (30 ng) of AahII. Therefore, according to the NC definition (see the Experimental section), 1 mg of NbAahII10 neutralized 125 μg of AahII or 37 000 LD 50 (i.e. 555 LD 50 AahII per nmol of NbAahII10) ( Table 2 ). The same Nb, at a molar ratio of only 1:1 to the AahII toxin, managed to neutralizes 100 % of the toxicity of 4 LD 50 and 50 % of our mice survived with 5 LD 50 ( Table 2) . These results correspond to a NC value of 133 000 LD 50 /mg of Nb or 2000 LD 50 /nmol of Nb. As would be expected, a Nb directed against AahI (NbAahI 22) which does not cross-react with the AahII in ELISA, failed to neutralize the AahII toxin.
Neutralization of AahII toxin by NbAahII10 tested by s.c. injection
Because of its high NC, the protective activity of NbAahII10 was further tested after s.c. injection of AahII mixed with this Nb. Taking into account that the LD 50 of AahII, s.c. injected in Swiss mice (20 g in weight) is 250 ng (instead of 3 ng for i.c.v. injection), we evaluated the neutralizing activity of the NbAahII10 at a fixed 4-fold molar excess to 1.5 LD 50 (375 ng), 2 LD 50 (500 ng) and 3 LD 50 (750 ng) of AahII. We show that 3 μg, 4 μg and 6 μg respectively, of the purified NbAahII10 are able to neutralize completely the lethal effect of the purified AahII toxin ( Table 3) .
Neutralization of the AahIIG50 toxic fraction by NbAahII10 tested by i.c.v. injection
Finally, we assessed the neutralization activity of the NbAahII10 on the AahG50. The heterogeneous AahG50 fraction contains different types of toxins (e.g. Na + , K + and Cl − channel blockers), which makes it difficult to measure the exact concentration of protein within this fraction. We considered that an attentuance at 280 nm of 1 corresponds to 0.54 mg/ml (the same molar absorption coefficient as for the pure AahII toxin), and found that the AahG50 had an LD 50 of 52 ng for i.c.v. injection and of 10 μg for s.c. injection. Because of the presence of various antigenically distinct molecules in the AahG50, it is impossible to neutralize all toxins with a monoclonal binder such as a Nb. However, the neutralization of the AahII, the most abundant and toxic molecule, within the AahG50 fraction by our NbAahII10 increases the number of survivors. For the i.c.v. injection of 1.5 LD 50 (∼ 78 ng) or 2 LD 50 (∼ 104 ng) AahG50 mixed with an estimated 10-fold excess of NbAahII10 over the AahII within AahG50, we noticed that 4 out of 4 and 2 out of 4 mice survived respectively (Table 3 ). For an s.c. injection that mimics more closely a scorpion sting, an injection of 15 μg of AahG50 (1.5 LD 50 ) killed all mice (4 out of 4), whereas 2 out of 4 mice survived when the same amount of AahG50 was mixed with an estimated 10-fold excess of our NbAahII10 (Table 3) .
DISCUSSION
The present paper reports the identification of a panel of Nbs with a high affinity and NC for AahII scorpion toxin. To obtain these toxin-neutralizing Nbs we immunized a dromedary with AahII toxin. From the blood lymphocytes of the hyperimmune animal we cloned the VHH repertoire of its HCAbs in a phagedisplay vector and selected multiple AahII-specific Nbs by phage-display panning.
In a previous study, Meddeb-Mouelhi et al. [31] used a heterogeneous AahG50 toxic fraction to immunize a dromedary and showed that the HCAb isotypes from the immune serum neutralized the scorpion toxin. This finding showed that it should be possible to clone and identify toxin-neutralizing singledomain antigen-binding entities derived from the HCAbs of the dromedary peripheral blood lymphocytes. The AahG50 fraction is still a complex mixture of several proteinaceous toxins of which the AahII is the most toxic molecule [5, 6] . Therefore we now preferred to use an enriched-AahII preparation to immunize a dromedary and a highly purified AahII toxin for subsequent boosts to elicit a strong and specific immune response against this antigen. The cloning of the VHH repertoire of an immunized camel or llama, and selection of the antigen-specific Nbs by phage display are well-established techniques [26, 32, 33, 35] . Following this procedure, we constructed immune VHH libraries and selected a panel of AahII-specific binders of high affinity.
With the exception of NbAahII38, having an affinity of 76 nM, all other binders had a single digit nanomolar or even subnanomolar equilibrium dissociation constant. Our AahII binders could be categorized in nine clusters according to the amino acid sequence homology within their CDR3. All members within a particular cluster recognize an overlapping epitope on the AahII toxin, as was demonstrated by BIAcore experiments, whereas the sequence variability within the CDR1 and CDR2 apparently leads to minor variations in antigen affinity. This finding confirms previous reports that showed how the CDR3 sequence within the Nb determines the CDR3 loop structure and thus the epitope specificity [37] by providing 60-80 % of the antigen-contacting area [38] . Differences in NC among the Nbs can be attributed to various factors (e.g. affinity, stability, bio-distribution or overlap between toxic and antigenic sites). In cases where several binders to toxic molecules are available, there is a strong tendency to favour that of highest affinity to develop the most potent toxin-neutralizing therapeutic. However, the present study clearly illustrates a lack of correlation between the NC and the binding properties (k on and k off rate constants, or K D , the equilibrium constant) of monovalent Nbs. It appears that the targeted epitope is far more crucial for optimal toxin neutralization. The importance of the antigenic site for Naja nigricollis toxin-neutralization was also highlighted in previous studies [39, 40] ; however, the NC of the intact monoclonals was not really linked to its kinetic rate binding parameters. The Nbs of our epitope clusters C, D and H, possessing most favourable binding characteristics to the AahII toxin perform poorly in the AahII toxin neutralization, as a 2-fold molar excess of Nb failed to protect the mice from 2-3 LD 50 when administered by i.c.v. injection. In contrast, NbAahII18, -05, -12, -19 and -20, the representatives of clusters F, G and I tested at a 2-4-fold molar excess, exhibited an intermediate NC corresponding to approx. 27 000 LD 50 per mg of Nb (or approx. 400 LD 50 per nmol of Nb). More interestingly, we demonstrated that NbAahII10 (cluster E) interacting with a topologically distinct epitope on the AahII possesses the highest NC (approx. 37 000 LD 50 per mg of Nb when tested at a molar AahII/Nb ratio of 1:4, or approx. 133 000 LD 50 /mg of Nb when evaluated at an equimolar ratio), despite binders of the other clusters exhibiting a faster k on rate or a higher affinity (lower K D ). Since the NbAahII10 is the binder with lowest k off rate (i.e. slowest dissociation of the AahII-Nb complex) it can be argued that this kinetic parameter is critical for the NC. However, a clear correlation between low k off and the better NC value is absent in our set of Nbs. For example, the strongneutralizing NbAahII10 and the non-neutralizing NbAahII38 have an equivalent k off rate (5.69 × 10 −4 and 7.81 × 10 −4 s −1 respectively). Likewise, the intermediate-neutralizing binders of cluster F, G and I, and the non-neutralizing binders of clusters C and D all have k off rates in the same range [(1.60-3.76) × 10 −3 s −1 ]. It was even noticed that, among the binders within cluster I associating to the same epitope, the NbAahII19 with the fastest k off rate performed best in a protection assay.
Our conclusion that the affinity and binding kinetics are less important parameters for toxin neutralization also explains why our Nb directed against the AahI with a moderate weak equilibrium dissociation constant of 58 nM reaches a NC of 17 800 LD 50 /mg of Nb [35] . However, we realize that this conclusion is at first sight contradictory to the results of the experiments by Juárez-González et al. [41] . These authors showed that an affinity maturation of a recombinant scFv (derived from a monoclonal antibody neutralizing scorpion toxin Cn2) from 1 nM to 75 pM (and all binding to the same epitope) has a beneficial effect on the mice survival ratio (protected/injected) when tested at a 10-fold molar excess to 1 LD 50 of Cn2 toxin. However, the superior NC could also result from the concomitant stabilization of the affinitymatured variant, as it was shown subsequently that stabilizing the scFv by changing its format into a Fab also improves its in vivo toxin neutralization performance [42] .
It is clear that the NbAahII10, which targets a unique epitope on AahII, is our best Nb to combat the lethal effect of this toxic molecule, probably because its epitope overlaps maximally with the AahII site which interacts with the synaptosomal voltagedependent sodium ion channel. In addition, it might be argued that the surface of the synaptosome receptor site of scorpion toxin has a higher complementarity to the unique antigen-binding site architecture of Nbs. Indeed, it has been repeatedly documented that Nbs often adopt a unique paratope shape targeting epitopes that are less antigenic for conventional antibodies [26, 33, 37, 38] .
According to our i.c.v. experiments, a mixture of 240 ng of NbAahII10 with 10 LD 50 of AahII (i.e. a 4 molar excess of Nb) neutralizes the lethality of this pure scorpion toxin in 50 % of the mice tested. By standard calculations [34] , this figure corresponds to an NC of 37 000 LD 50 of AahII/mg of Nb (or 560 LD 50 per nmol of Nb). Although the NC values calculated according to this approach are convenient to evaluate batch-to-batch variability of antiserum preparations, they cannot be used to compare the therapeutic potency of different neutralizing antibody fragment formats (i.e. scFv, Fab and Nb) or, when tested on different toxins, alternative injection routes [i.p. (intraperitoneal), i.c.v. and s.c.], or at a different ratio of toxin to antibody. Nevertheless, the complete neutralization of 7 LD 50 with a 4 molar excess of Nb, or even 4 LD 50 at an equimolar amount of Nb upon i.c.v. injection remains impressive. A similar potent neutralization of AahII was noticed with this Nb after s.c. administration of the mixture, which is more relevant as it mimics more closely a scorpion sting. Here, 3 LD 50 of the toxin were entirely neutralized with a 4 molar excess of the Nb in all mice. These values demonstrate the potency of our NbAahII10 and it is clear that the neutralization of such high LD 50 at this low molar excess of antibody were never reached so far with other scorpion toxins, or monoclonal antibody fragments in a scFv or Fab format [22] [23] [24] [25] 41, 42] .
Additional benefits of Nbs to develop a toxin immunotherapeutic are to be found in their high production yields in bacteria or yeasts [43] [44] [45] and a safe and well-tolerated use in human volunteers without dose-limiting toxicities or serious adverse events (see press-release December 2007 at www.ablynx.com). Evidently, for human treatment it is advisable to 'humanize' the Nbs that, after all, originate from dromedary antibodies and a generic humanization procedure has recently been developed [46] .
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